Werewolf Therapeutics (HOWL) Total Non-Current Liabilities (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Total Non-Current Liabilities of $7.9 million for Q2 2026, down 83.78% year-over-year from $48.5 million in Q2 2025, and down 82.81% on a QoQ basis from $45.7 million in Q1 2026.
Werewolf Therapeutics (HOWL) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $7.9 million in Q2 2026.
- Total Non-Current Liabilities for Q2 2026 came in at $7.9 million, down 83.78% year-over-year; the trailing twelve-month figure through Jun 2026 was $7.9 million (down 83.78% YoY), and the FY2025 annual result was $43.8 million, down 13.56% from the prior year.
- Total Non-Current Liabilities fell to $7.9 million in Q2 2026, from $45.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $74.0 million in Q1 2023 and troughed at $7.9 million in Q2 2026.
- A 5-year average of $48.6 million and a median of $47.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities jumped 411.14%; it then tumbled 83.78% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $37.7 million in 2022, then surged by 68.25% to $63.5 million in 2023, then decreased by 20.09% to $50.7 million in 2024, then slipped by 13.56% to $43.8 million in 2025, then sank by 82.06% to $7.9 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $7.9 million in Q2 2026, $45.7 million in Q1 2026, and $43.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 7.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.86 Mn |
| Mar 31, 2026 | 45.74 Mn |
| Dec 31, 2025 | 43.83 Mn |
| Sep 30, 2025 | 47.40 Mn |
| Jun 30, 2025 | 48.46 Mn |
| Mar 31, 2025 | 47.27 Mn |
| Dec 31, 2024 | 50.71 Mn |
| Sep 30, 2024 | 47.92 Mn |
| Jun 30, 2024 | 46.84 Mn |
| Dec 31, 2023 | 63.46 Mn |
| Sep 30, 2023 | 63.94 Mn |
| Jun 30, 2023 | 66.64 Mn |
| Mar 31, 2023 | 74.00 Mn |
| Dec 31, 2022 | 37.72 Mn |
| Sep 30, 2022 | 41.29 Mn |
| Jun 30, 2022 | 45.30 Mn |
| Dec 31, 2021 | 26.46 Mn |
| Sep 30, 2021 | 9.07 Mn |
| Jun 30, 2021 | 8.86 Mn |
| Mar 31, 2021 | 7.09 Mn |